Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
OLIG2
REST API REST API
Homo sapiens
OLIG2 is differentially expressed in 177 experiments: 151 organism parts: amygdala, hypothalamus, ... (149 more);, 118 disease states: normal, acute myeloid leukemia, ... (116 more);, 50 cell types 152 cell lines 20 compound treatments and 71 other conditions.
Synonyms PRKCBP2, RACK17, bHLHe19, OLIGO2, BHLHB1
Orthologs Olig2 (Mus musculus)   olig2 (Danio rerio)   Olig2 (Rattus norvegicus)   olig2 (Xenopus laevis)   (Compare orthologs)
Gene Ontology Term plasma membrane, DNA binding, protein binding, regulation of transcription, DNA-dependent, cytoplasm, transcription, DNA-dependent, multicellular organismal development, nucleus, nervous system development, protein homodimerization activity, negative regulation of transcription from RNA polymerase II promoter, oligodendrocyte differentiation, myelination, spinal cord oligodendrocyte cell fate specification, positive regulation of oligodendrocyte differentiation, negative regulation of neuron differentiation, spinal cord oligodendrocyte cell differentiation, neuron fate commitment, sequence-specific DNA binding transcription factor activity, HMG box domain binding, sequence-specific distal enhancer binding RNA polymerase II transcription factor activity
InterPro Term HLH_DNA-bd
UniProt Accession Q13516, C9J444, Q05BP9
Search EB-eye ENSG00000205927
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-GEOD-803, E-MTAB-24, E-MTAB-25, E-GEOD-7540, ... (18 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-1880, E-GEOD-19639, E-GEOD-2450, E-GEOD-24147, ... (21 experiments)

Factor Value U/D Experiments
U87
2
E-MEXP-903, E-GEOD-20089
HL-60
1
2
E-GEOD-24147, E-GEOD-5258, E-MTAB-37
GA10
1
E-MTAB-37
HMCB
1
E-MTAB-37
SW480
1
E-MTAB-37
MCCAR
1
E-MTAB-37
146 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-3920, E-GEOD-360, E-GEOD-20677, E-GEOD-13987, ... (31 experiments)

Factor Value U/D Experiments
stromal cell
2
E-MEXP-2034, E-GEOD-10797
fibroblast
2
E-GEOD-3920, E-GEOD-26672
leydig cell
1
E-MTAB-25
LCC
1
1
E-GEOD-19188
cardiac myocyte
1
E-AFMX-5
BDCA4+ dentritic cells
1
1
E-AFMX-5
44 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-2508, E-GEOD-15960, E-GEOD-2466, ... (42 experiments)

Factor Value U/D Experiments
embryonal rhabdomyosarcoma
2
E-MEXP-121, E-MTAB-62
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-995
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
synovial sarcoma
1
E-GEOD-6481
malaria
1
E-MTAB-62
oligodendroglioma with 1p19q codeletion
1
E-MEXP-1507
112 more value(s).


Compound treatment

studied in E-MEXP-1269, E-GEOD-5258, E-GEOD-3284, E-GEOD-412, E-GEOD-2803, ... (12 experiments)

Factor Value U/D Experiments
none
1
3
E-TABM-868, E-GEOD-412, E-GEOD-2803, E-GEOD-995
all-trans retinoic acid
1
1
E-GEOD-995
5-fluorouridine
1
1
E-GEOD-995
5-aza-2'-deoxycytidine + trichostatin A
2
1
E-MEXP-1269
glutamine
1
E-MEXP-941
no estradiol
1
E-GEOD-20081
14 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
28
2
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21589

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-2191, E-GEOD-21374, ... (7 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-1561, E-TABM-147

Environmental stress
studied in E-GEOD-1643

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-4006

Genotype
studied in E-GEOD-2466, E-TABM-868, E-GEOD-1153

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234

Individual
studied in E-MTAB-197, E-GEOD-2466, E-MEXP-2069, E-GEOD-16363, E-GEOD-430, ... (28 experiments)

Infection
studied in E-GEOD-2405

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056, E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

No of metastases
studied in E-GEOD-22541

No of pulmonary metastases
studied in E-GEOD-22541

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004

Phenotype
studied in E-GEOD-1309, E-GEOD-21750, E-GEOD-1657

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19246

Replicate
studied in E-GEOD-10797

RNAi
studied in E-MEXP-101, E-GEOD-3697, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-1561

Processing time: 0.42 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM